减剂量与高剂量糖皮质激素联合利妥昔单抗诱导ANCA相关性血管炎缓解:预设2年随访研究
LoVAS试验预设2年随访显示,新发且无严重肾小球肾炎或肺泡出血的ANCA相关性血管炎患者中,减剂量泼尼松龙联合利妥昔单抗组与高剂量组24个月复发率无显著差异,减剂量组严重不良事件更少,源于6个月诱导期事件率较低。
要点
- 减剂量组89.7%停用泼尼松龙,高剂量组15.5%停用,中位停药时间分别为150天和375天。
- 24个月内减剂量组复发9例(13.0%),高剂量组5例(7.6%),差异无统计学意义(p=0.311)。
- 减剂量组严重不良事件19例患者36次(27.5%),少于高剂量组30例患者54次(46.2%)(p=0.025)。
核心结论
- 24个月时两组复发频率无差异,减剂量组严重不良事件更少,归因于6个月诱导期事件率较低。
- 试验人群髓过氧化物酶-ANCA阳性偏倚(85.8%)应予注意。
研究设计与样本
- LoVAS试验的预设2年随访研究,共140例新发ANCA相关性血管炎患者(无严重肾小球肾炎或肺泡出血)随机分组。
- 减剂量组接受泼尼松龙0.5 mg/kg/天联合利妥昔单抗375 mg/m2/周×4,高剂量组接受泼尼松龙1 mg/kg/天联合利妥昔单抗。
- 达到缓解后接受利妥昔单抗维持治疗1 g/6个月,共134例纳入分析。
主要发现
- 达到方案治疗缓解的患者中,减剂量组89.7%停用泼尼松龙,高剂量组15.5%停用,中位停药时间分别为150天和375天。
- 24个月试验期间,减剂量组2例(2.8%)死亡,高剂量组5例(7.6%)死亡(p=0.225)。
- 减剂量组复发9例(13.0%,其中重大2例、轻微7例),高剂量组复发5例(7.6%,其中重大2例、轻微3例)(p=0.311)。
- 减剂量组严重不良事件为19例患者共36次(27.5%),高剂量组为30例患者共54次(46.2%)(p=0.025)。
局限性
- 试验人群存在髓过氧化物酶-ANCA阳性偏倚(85.8%),应予注意。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The LoVAS trial reported non-inferiority in remission induction rates between the reduced-dose and conventional high-dose glucocorticoid regimens plus rituximab for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis at 6 months; however, maintenance glucocorticoid requirements and long-term outcomes are unknown. METHODS: A total of 140 patients with new-onset ANCA-associated vasculitis without severe glomerulonephritis or alveolar haemorrhage were randomised to receive reduced-dose prednisolone (0.5 mg/kg/day) plus rituximab (375 mg/m2/week×4) or high-dose prednisolone (1 mg/kg/day) plus rituximab. After achieving remission, patients received the rituximab maintenance therapy (1 g/6 months). RESULTS: A total of 134 patients were analysed. Among patients who achieved remission with the protocolised treatments, the majority of patients in the reduced-dose group (89.7%) and 15.5% in the high-dose group discontinued prednisolone (median time to withdrawal, 150 and 375 days, respectively). During 24-month trial period, two patients in the reduced-dose group (2.8%) died, while five patients in the high-dose group (7.6%) died (p=0.225). Relapse occurred in nine patients in the reduced-dose group (13.0%) (two major and seven minor) and five in the high-dose group (7.6%) (two major and three minor) (p=0.311). Serious adverse events (SAEs) were less frequent in the reduced-dose group (36 events in 19 patients, 27.5%) than in the high-dose group (54 events in 30 patients, 46.2%) (p=0.025). CONCLUSION: At 24 months, frequencies of relapse did not differ between the groups, and SAEs were less frequent in the reduced-dose group due to the lower event rate in the 6-month induction phase. The bias to myeloperoxidase-ANCA positivity (85.8%) in the trial population should be noted. TRIAL REGISTRATION NUMBER: NCT02198248.
引用
- Furuta S, Nakagomi D, Kobayashi Y, et al. Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study. Ann Rheum Dis. 2024. PMID: 37734880. doi:10.1136/ard-2023-224343
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。